Breast Cancer Clinical Trials in Salt Lake City

Showing 141-160 of 556 trials

RECRUITINGPhase 2< 1 mile

5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer

NCT06961955

The goal of this study is to evaluate 5 days vs. 9 days of whole breast radiation.

Breast CancerInvasive Carcinoma of BreastDuctal Breast Carcinoma in Situ

University of Utah144 participantsStarted May 2025

Salt Lake City, Utah, United States

TERMINATEDPhase 2< 1 mile

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

NCT04916002

The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: * How many participants' cancers respond to vidutolimod together with cemiplimab? * Is vidutolimod together with cemiplimab safe and well-tolerated? * How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have a follow-up visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.

Merkel Cell CarcinomaCutaneous Squamous Cell CarcinomaBasal Cell Carcinoma+3 more

Regeneron Pharmaceuticals77 participantsStarted Nov 2021

Birmingham, Alabama, United States • Duarte, California, United States • La Jolla, California, United States +21 more locations

5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer

A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer

Breast Cancer Trials in Other Cities

The Impact of Intraoperative Methadone on Postoperative Opioid Use

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer

A Study of PF-06873600 in People With Cancer

A Trial of 15 Fraction vs 25 Fraction Pencil Beam Scanning Proton Radiotherapy After Mastectomy in Patients Requiring Regional Nodal Irradiation

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

Women Informed to Screen Depending on Measures of Risk (Wisdom Study)

QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients

Mirai-MRI: Validation of AI Models for Breast Cancer Risk

Study of AVZO-021 in Patients With Advanced Solid Tumors

MARGetuximab Or Trastuzumab (MARGOT)

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Other Conditions in Salt Lake City